Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people starting tirzepatide (Mounjaro) experience some side effects, particularly in the first few weeks. The NHS describes a GI-led profile — nausea, diarrhoea and constipation are the most commonly reported — that tends to ease as your body settles at each dose level. Mounjaro is a prescription-only medicine; a prescriber assesses your full health picture before it's issued, and knowing what to expect matters just as much as knowing when to act.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Picture the evening after your first Mounjaro injection. You've put the pen back in the fridge door and gone about your day, and then (maybe that night, maybe the next morning) your stomach feels unsettled. That's a normal, well-documented response. Tirzepatide slows how quickly food leaves the stomach, and your gut takes time to adapt.
The NHS tirzepatide medicines page lists the very common side effects (affecting more than one in ten people) as nausea, diarrhoea, vomiting, constipation, stomach pain and indigestion. Fatigue, dizziness and headache appear less often. Injection-site reactions (mild redness or itching where the needle went in) are also reported. None of these is a reason to panic, but all of them are worth logging so you can describe them accurately to your prescriber.
The pattern tends to follow dose changes. Symptoms are usually most noticeable in the first few days after a new strength, then fade. By the time the next step-up comes around, most people find they've acclimatised. If nausea is an issue, eating smaller portions and avoiding rich or fatty meals during the adjustment window is practical advice, though your prescriber and the Patient Information Leaflet are the right places to get personalised guidance on managing it.
You can read more about the full side-effect landscape on our detailed Mounjaro side effects page.
The side effects above are expected. These are not.
Seek urgent medical attention (call 111 or go to A&E) if you develop severe, persistent stomach pain that radiates toward your back, with or without vomiting. This is the presentation associated with acute pancreatitis. In January 2026, the MHRA published a Drug Safety Update specifically flagging pancreatitis as a known but infrequent risk with GLP-1 receptor agonists, tirzepatide included. It's rare, but the pain profile is distinctive and shouldn't be waited out.
Other situations that need prompt attention: signs of an allergic reaction (swelling of the face, throat or tongue, difficulty breathing, severe skin reaction); symptoms suggesting dehydration if you've had severe vomiting or diarrhoea, dizziness when standing, very dark urine, passing very little urine; and persistent gallbladder pain (sharp right-sided or central upper abdominal discomfort, sometimes with yellowing of the skin). Contact your GP or call 111 for any of these. If you want a clearer picture of what to expect before those situations arise, our guide to Mounjaro injection side effects and NHS guidance covers the full range in plain language. In an emergency, call 999.
If you have concerns outside of a medical emergency, the nume support team is available seven days a week, and your prescriber can review whether a side effect warrants a dose pause or any other change.
Mounjaro carries a Black Triangle (▼) designation in the UK, which means the MHRA requires enhanced monitoring while post-marketing safety data continues to accumulate. This is standard for newer medicines and reflects caution, not concern about established safety. The full side-effect and contraindication information is published in the Mounjaro Summary of Product Characteristics on the electronic Medicines Compendium (eMC), that document is what UK prescribers refer to.
Mounjaro is not currently available routinely through a GP for most people; the NHS is rolling it out in phased cohorts. Details of who currently qualifies, and what those NHS phases look like, are covered on our Mounjaro on the NHS page. For those who don't meet the current NHS criteria or prefer not to wait, a private prescription route through a regulated pharmacy is the legal alternative, and our guide to getting Mounjaro through a GP or online explains the difference between those routes clearly. If you're also weighing up the cost and availability across different providers, our comparison of where to buy Mounjaro online in the UK sets out the key differences clearly. For anyone who does qualify through the health service, our page on how to buy Mounjaro through the NHS walks through the process step by step.
The MHRA also runs the Yellow Card scheme, where patients (not just healthcare professionals) can submit reports of suspected side effects. If something unexpected happens on treatment, reporting it contributes to the national safety picture. The link is yellowcard.mhra.gov.uk.
At nume, our prescribers go through every aspect of side-effect risk with you as part of the consultation, and they're reachable afterwards if something concerns you. If you'd like to talk through whether Mounjaro is suitable for your health picture, check your eligibility with a free consultation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.